ALKBH5 and melanoma: A recent study found that in anti-PD-1 therapy for melanoma, the deletion of ALKBH5 decreased the levels of infiltrating Tregs and polymorphonuclear myeloid derived suppressor cells (PMN-MDSCs), while the level of dendritic cells increased.